A phase II study of the combination of Rituximab, Mitoxantrone, Etoposide, and Prednisolone for relapsed elderly patients with diffuse large B-cell lymphoma (R-MEP07)
Phase 2
- Conditions
- Diffuse large B-cell lymphoma
- Registration Number
- JPRN-UMIN000001050
- Lead Sponsor
- Clinical Hematology Study Group of National Hospital Organization (CHSG-NHO)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1) CNS involvement 2) History of glaucoma 3) History of severe drug allergy 4) Active infectious diseases 5) HIV or HTLV-1 positive 6) HBs antigen or HCV antibody positive 7) Significant complications which include cardiac dysfunction, liver cirrhosis, uncontrolled diabetes, renal failure 8) Interstitial pneumonitis or fibrosis 9) History of other active malignancy 10) Severe mental disorder 11) Regular use of systemic steroids 12) Inadequate physical condition, as diagnosed by primary physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method